Pathstone Family Office’s CRISPR Therapeutics CRSP Stock Holding History

Pathstone Family Office’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,896	Closed	-$516K	–	1513
2022 Q3	$516K	Buy	7,896 +3,981	+102%	+$289K	﹤0.01%	1064
2022 Q2	$238K	Sell	3,915 -21,550	-85%	-$1.27M	0.01%	883
2022 Q1	$1.6M	Buy	25,465 +21,464	+536%	+$1.35M	0.04%	212
2021 Q4	$303K	Buy	4,001 +1,976	+98%	+$173K	0.01%	705
2021 Q3	$226K	Buy	2,025 +364	+22%	+$45.7K	0.01%	774
2021 Q2	$269K	Buy	+1,661	New	+$202K	0.01%	682

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pathstone Family Office's CRSP Position: Q4 2022 in Review

Pathstone Family Office sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 7,896 shares — an estimated $516K sold.

Pathstone Family Office first reported a position in CRSP in Q2 2021 and held it in 6 quarters. The position peaked at $1.6M in Q1 2022. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Pathstone Family Office reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Pathstone Family Office sold 7,896 CRISPR Therapeutics shares in Q4 2022, an estimated $516K.
Pathstone Family Office first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 6 quarters.
Pathstone Family Office's CRISPR Therapeutics position peaked at $1.6M in Q1 2022.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Pathstone Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.